Sept. 9, 2004 – Epoch Biosciences Inc. has agreed to merge into Nanogen Inc., according to a news release.

Nanogen, a San Diego developer of microarrays with integrated electronics and workstations, will offer a price of $2 per Epoch share. Epoch shareholders will receive a number of Nanogen shares based on an exchange ratio determined by dividing the offering price by Nanogen’s issue price at closing.

The merger, subject to stockholder approval and other conditions, is expected to close by year’s end. Nanogen said the deal would expand its reach in clinical lab and research markets.

Epoch, a developer of genomic and molecular diagnostic technologies, will maintain research and development, as well as reagent manufacturing operations in Bothell, Wash. Administrative, marketing and sales departments will move to Nanogen’s San Diego headquarters, the release said.